Pain Management

ZTlido (lidocaine topical system) shows superior adhesion compared with other topical non-opioid pain patches.

Kempharma introduces newly approved pain management drug and warns of risk for addiction.

Although it is unclear what constitutes “unusual or disproportionate,” such phrases are particularly disturbing when we realize that the regulation of medical practice is a traditional state function, not a federal one.

Surgical patients can exhibit anxiety about the medications they will be started on following surgery. Pharmacists are in a position to address those concerns to the benefit of all.

Migraine is a condition characterized mainly by severe and recurrent headaches. Approximately 12% of the general population experiences migraines, with a higher frequency in women than men.

Chronic pain patient may respond to endogenous opioids differently than healthy people.

More than 75% of patients who undergo surgery experience moderate to severe acute postoperative pain that begins immediately following surgery and may extend beyond hospital discharge.

Hyperactivity in the brain networks of patients with fibromyalgia is to blame for patients with chronic pain.

Migraine pain may be caused by nerves trapped between muscles, bones, and fascia, which could be reduced by forehead restoration surgery.

A look at the different receptor bindings that affect analgesic effect.

Those familiar with the technology hope that the concept will develop enough that it can be integrated into daily life, as with an Apple Watch or a smartphone.

This article highlights several key therapeutics areas with Sublocade that every pharmacist should know.

The established therapeutic dosing for gabapentin in neuropathic pain is 1800-3600 mg/day in 3 divided doses in patients with normal renal function.

Fosfomycin (Monurol) is an antibiotic that uses a unique mechanism of action to establish its bactericidal activity.

When available treatment guidelines for patients with cancer are followed, 70% to 90% can achieve adequate pain relief.

The FDA is investigating the medical food product for serious adverse effects. A pharmacist can convey this information to patients.

Here are ways for pharmacists to relieve foot and leg aches after a long shift.

Initiation of treatment with guideline-recommended medications within 60 days of fibromyalgia diagnosis was associated with immediate annual healthcare cost savings.

Genome sequencing may be fundamental to eventually offering precision medicine to patients with rheumatoid disease, but it will only reveal part of the patient’s health story.

State and local marijuana laws continue to evolve toward legalization much faster than the scientific community can collect the data to help society weigh the health, safety, and ethical ramifications of these new laws.

The findings demonstrated that female gender, older age, and Caucasian race were the most likely predictors of opioid use in patients with JFMS.

Patients with rheumatoid arthritis (RA) who took biologics or triple therapy had a longer fail time than patients who took methotrexate oral monotherapy, suggesting that these treatments may be a good follow-up to failed first-line methotrexate treatment.

Physician and pharmacist collaboration is key within the complex pain management prescribing landscape.

Golimumab is the only fully-human anti-tumor necrosis factor (TNF) alpha therapy that is administered with a 30-minute infusion.

This year, the FDA is on pace to approve about 38 new medications. Here is a look at 6 of these.

This year, the FDA is on pace to approve about 38 new medications. Here is a look at 6 of these.

Breakthrough pain estimates vary, but as many as 50% of patients diagnosed with cancer and chronic pain have pain levels that are not adequately controlled

Here is how to distinguish between those who need prescriptions to manage pain and those seeking controlled substances for illicit reasons.

The tablets did not get approval for managing fibromyalgia, however, according to a press release from Pfizer.

It is currently the first and only extended-release, intra-articular injection available for OA.